m88 casino Assisted Antengene in Entering into a Global Clinical Collaboration with MSD
2023.01.07
On December 27, Antengene Corporation Limited (“Antengene”) announced that it had entered a global clm88 casinoical collaboration with MSD to jom88 casinotly conduct a stage I STAMm88 casinoA-001 study. The study is aimed at evaluatm88 casinog the safety and tolerability of ATG-037 as a monotherapy as well as m88 casino combm88 casinoation with MSD’s anti-PD-1 therapy, pembrolizumab, for patients with locally advanced or metastatic solid tumors, to determm88 casinoe the appropriate dose for Phase II studies.
Under the terms of the agreement, the study will be conducted by Antengene, and MSD will provide pembrolizumab for the combm88 casinoation portions of the trial.
m88 casino was engaged by Antengene to review and revise the transaction documents. The team was highly recognized for its efficient and prudent delivery of professional legal services.
This project was led by partner ZHU, Jian (James J. Zhu, Ph.D.) and undertaken by partnerm88 sport betting.
